



TELEPHONE INFORMATION SESSION ON VIDAZA[®]

PRESENTED BY

DR. BRIAN LEBER

CLINICAL HEMATOLOGIST, PROFESSOR OF MEDICINE AT MCMASTER UNIVERSITY
MEDICAL CENTRE AND THE JURAVINSKI CANCER CENTRE

JULY 12TH 2010 AT 7:00 – 8:00 PM EST

Vidaza[®] (Azacitidine), manufactured by pharmaceutical company Celgene, is an exciting new therapy in the treatment of Myelodysplastic Syndrome (myelodysplasia or MDS) and Acute Myeloid Leukemia (AML). On October 23, 2009, Health Canada issued a Notice of Compliance to Celgene for the drug product, Vidaza[®]. I am pleased to announce that the Alberta and Ontario provincial governments have recently agreed to add Vidaza[®] to their respective formularies for public funding of this drug.

From the Health Canada website:

Vidaza[®] is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with:

- *Intermediate-2 and High-risk Myelodysplastic Syndrome according to the International Prognostic Scoring System.*
- *Acute Myeloid Leukemia with 20-30 % blasts and multi-lineage dysplasia, according to the World Health Organization classification.*

On July 12th at 7:00 pm EST, the Aplastic Anemia and Myelodysplasia Association of Canada (AAMAC) will be hosting a national phone teleconference where Dr. Leber will present the latest information on the efficacy and application of Vidaza[®]. All interested patients, care givers and health care providers are invited to participate in the call.

If interested, please contact Stan Chmelyk (President, AAMAC) for the toll-free number and access code to use for the teleconference:

Email - schmelyk@sympatico.ca

Phone – 905-457-9858

There will be time at the end of Dr. Leber's presentation for a limited number of general questions.